The long-term goal of the Breast Cancer (BC) Program is to elucidate the biology, genetics and biochemistry of breast cancer, and to apply this knowledge towards diagnostic, therapeutic and preventive strategies. To achieve this end, the following Specific Goals will be pursued: 1) To identify aberrant regulatory pathways in breast cancer pathogenesis. Specifically, by analyzing tumor biopsies and model systems, we will dissect the pathways responsible for distinct subtypes of breast cancer and elucidate their mechanistic role in tumor development. 2) To optimize the treatment and prevention of breast cancer. By using tissue, serum and imaging-based biomarkers, we will identify suitable patients for targeted therapy and then measure its efficacy. 3) To improve the quality of breast cancer care. By using novel methodologies to characterize the short and long term risks associated with standard breast cancer treatment, we will conduct clinical trials to evaluate novel interventions to diminish these effects. Since the prior grant period, the number of institution-based clinical trials in breast cancer and the number of patients accrued to therapeutic and supportive care trials has increased, with several investigators leading multi-center national and local trials. Over 12% of all patients, and 39% of eligible patients, are enrolled on trials. A noteworthy feature of the clinical research is minority accrual to clinical trials, with 58% of patients enrolled in trials identified as either African-American or Hispanic. The BC program consists of 29 members (16 full members, 12 clinical members, and 1 associate member) from fourteen departments within the College of Physicians &Surgeons, the Mailman School of Public Health and the College of Dental Medicine at Columbia University. The Program is supported by large program project grants, including a breast cancer NCI P01 focused on signaling pathways in breast cancer and a DoD Center of Excellence focused on disparities in breast cancer treatment. For the last budget year of the grant (July 1, 2006 - June 30, 2007), the BC Program received a total of $7.9M (direct costs) in cancer-relevant grant support, including $2.6M (direct costs) in NCI funding, $3.2M (direct costs) in other cancer-related peer-reviewed funding, and $2.1M (direct costs) in cancer-related non-peer-reviewed funding. The total number of publications since the previous submission (i.e., 2003- present) was 177, of which 18.6% were intra-programmatic and 40.7% % inter-programmatic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA013696-39S3
Application #
8637162
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-07-04
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
39
Fiscal Year
2013
Total Cost
$136,392
Indirect Cost
$51,147
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Bassuk, Alexander G; Zheng, Andrew; Li, Yao et al. (2016) Precision Medicine: Genetic Repair of Retinitis Pigmentosa in Patient-Derived Stem Cells. Sci Rep 6:19969
Zhang, Lijuan; Du, Jianhai; Justus, Sally et al. (2016) Reprogramming metabolism by targeting sirtuin 6 attenuates retinal degeneration. J Clin Invest 126:4659-4673
Planet, Paul J; Parker, Dane; Cohen, Taylor S et al. (2016) Lambda Interferon Restructures the Nasal Microbiome and Increases Susceptibility to Staphylococcus aureus Superinfection. MBio 7:e01939-15
Canetta, S; Bolkan, S; Padilla-Coreano, N et al. (2016) Maternal immune activation leads to selective functional deficits in offspring parvalbumin interneurons. Mol Psychiatry 21:956-68
Joseph, Leroy C; Barca, Emanuele; Subramanyam, Prakash et al. (2016) Inhibition of NAPDH Oxidase 2 (NOX2) Prevents Oxidative Stress and Mitochondrial Abnormalities Caused by Saturated Fat in Cardiomyocytes. PLoS One 11:e0145750
Gelman, Rony; Tsang, Stephen H (2016) SEQUENTIAL CENTRAL RETINAL VEIN AND OPHTHALMIC ARTERY OCCLUSIONS IN A PEDIATRIC CASE OF PRIMARY ANTIPHOSPHOLIPID SYNDROME. Retin Cases Brief Rep 10:58-62
Grillo, Lola M; Nguyen, Huy V; Tsang, Stephen H et al. (2016) Cobalt-Chromium Metallosis With Normal Electroretinogram. J Neuroophthalmol 36:383-388
Wert, Katherine J; Mahajan, Vinit B; Zhang, Lijuan et al. (2016) Neuroretinal hypoxic signaling in a new preclinical murine model for proliferative diabetic retinopathy. Signal Transduct Target Ther 1:
Moshfegh, Yasmin; Velez, Gabriel; Li, Yao et al. (2016) BESTROPHIN1 mutations cause defective chloride conductance in patient stem cell-derived RPE. Hum Mol Genet 25:2672-2680
Higuchi-Sanabria, Ryo; Swayne, Theresa C; Boldogh, Istvan R et al. (2016) Imaging of the Actin Cytoskeleton and Mitochondria in Fixed Budding Yeast Cells. Methods Mol Biol 1365:63-81

Showing the most recent 10 out of 214 publications